INT51280

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 1993
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 2.54
Pain Relevance 2.11

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
temporomandibular joint 1
Igkv11-125 (Mus musculus)
Pain Link Frequency Relevance Heat
qutenza 84 98.16 Very High Very High Very High
antagonist 42 98.00 Very High Very High Very High
Cannabinoid receptor 69 97.60 Very High Very High Very High
Cannabinoid 48 97.52 Very High Very High Very High
Snapping jaw 2 95.12 Very High Very High Very High
Intracerebroventricular 6 79.28 Quite High
substance P 27 5.00 Very Low Very Low Very Low
c fibre 18 5.00 Very Low Very Low Very Low
agonist 12 5.00 Very Low Very Low Very Low
IPN 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Infection 65 100.00 Very High Very High Very High
Sprains And Strains 82 99.18 Very High Very High Very High
Cough 192 97.48 Very High Very High Very High
Temporomandibular Joint Syndrome 2 95.12 Very High Very High Very High
Disease 1 77.80 Quite High
Flavivirus Infection 1 73.32 Quite High
Dengue 7 50.00 Quite Low
Dengue Hemorrhagic Fever 4 5.00 Very Low Very Low Very Low
Immunization 2 5.00 Very Low Very Low Very Low
Virus Diseases 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As shown in Fig. 2, VDM11 at doses of 3, 6 and 10 mg/kg, subcutaneously, produced a dose-dependent inhibition of the number of capsaicin-induced coughs (Fig. 2).
Gene_expression (produced) of VDM11 associated with qutenza and cough
1) Confidence 0.11 Published 2006 Journal Cough Section Body Doc Link PMC1448189 Disease Relevance 0.66 Pain Relevance 0.68
Pretreatment with SR141716A, a cannabinoid CB1 receptor antagonist, at doses of 0.3, 1.0 and 3 mg/kg, intraperitoneally, dose-dependently antagonized the antitussive effect of VDM11 (10 mg/kg, subcutaneously) (Fig. 3).
Gene_expression (effect) of VDM11 associated with cannabinoid receptor, antagonist and cannabinoid
2) Confidence 0.11 Published 2006 Journal Cough Section Body Doc Link PMC1448189 Disease Relevance 0.55 Pain Relevance 0.59
Effects of SR141716A on the antitussive effects of VDM11
Gene_expression (effects) of VDM11
3) Confidence 0.11 Published 2006 Journal Cough Section Body Doc Link PMC1448189 Disease Relevance 0.60 Pain Relevance 0.67
In the laboratory we have three mosquito strains with different susceptibilities to DENV infection (DS3, DMEB and IBO-11) and these have allowed us to determine whether MG cell receptors for DENV may be markers of vector competence.
Gene_expression (infection) of IBO-11 associated with sprains and strains and infection
4) Confidence 0.01 Published 2008 Journal BMC Microbiol Section Body Doc Link PMC2488350 Disease Relevance 0.57 Pain Relevance 0
Four hybrid cell lines producing monoclonal antibodies (designated AC2, AH12, DB10 and DD11) were derived from mice immunized with the large chondroitin sulphate proteoglycan isolated and purified from the bovine temporomandibular joint disc.
Gene_expression (producing) of DD11 in temporomandibular joint associated with snapping jaw
5) Confidence 0.01 Published 1993 Journal Matrix Section Abstract Doc Link 7687000 Disease Relevance 0.17 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox